Magnitude of Low-density Lipoprotein Reduction and Impact on Major Cardiovascular Outcomes

J Cardiovasc Pharmacol. 2023 Jan 1;81(1):15-17. doi: 10.1097/FJC.0000000000001376.
No abstract available

MeSH terms

  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular System*
  • Cholesterol, HDL
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Lipoproteins, LDL
  • Risk Factors

Substances

  • Lipoproteins, LDL
  • Cholesterol, HDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors